2020 Jul 22;12(8):2178
In study A, of the 12 participants who received at least one dose of 3 mg orforglipron, two participants (16.7%) experienced at least one TEAE in the fasted condition: two participants (16.7%) experienced nausea, one participant each (8.3%) experienced upper abdominal pain, dizziness, headache, oropharyngeal pain, sneezing, and vomiting (Table 5, Table S1 in Supplementary material)
People who have had weight loss already and are in a maintenance phasemicrodosing or lower dose may help sustain results
Focus on your progress, not someone elses timeline
Since L-glutamine is a precursor to L-glutathione, they can work together to support both the structure and the protection of your cells
Recognizing When Appetite Loss Becomes a Problem Mild appetite reduction is expected and desired during tirzepatide treatment, but distinguishing between therapeutic hunger control and problematic under-eating is critical